ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Abstract: TH-PO405

Hepcidin Response to IV Iron Is Different in CKD Compared with Pregnancy and Healthy Controls

Session Information

Category: Nutrition, Inflammation, and Metabolism

  • 1401 Nutrition, Inflammation, Metabolism


  • McMahon, Lawrence P., Eastern Health, Box Hill, Victoria, Australia
  • Huang, Louis L., Eastern Health, Box Hill, Victoria, Australia
  • Lee, Darren H.K., Eastern Health, Box Hill, Victoria, Australia
  • Macdougall, Iain C., King's College Hospital, London, United Kingdom

The IDENTIFY Study investigated the effects of IV ferric carboxymaltose (FCM) on markers of bone metabolism in chronic kidney disease (CKD), pregnancy, and healthy controls, but data on iron status were also collected. When the results of the latter were analysed, it became clear that there were differences among the three groups of patients, and the aim of this analysis was to examine this in more detail.


IDENTIFY was a prospective observational study comprising 1g of IV FCM administered to 3 patient populations: CKD (n=25); healthy Controls (n=20); and Pregnancy (n=20). The following markers of iron status were collected on days 0, 2, 7 and 21: serum iron, ferritin, transferrin saturation (TSAT) and hepcidin (by mass spectrometry).


Following IV FCM, there was a similar increase in serum iron and TSAT in all groups, which peaked at day-2, and returned to baseline at day-7. Ferritin increased to the same extent in all groups, reaching a maximum at day-7, and remaining significantly above baseline at day-21. Serum hepcidin peaked at day-2 in all groups, but the zenith varied (127±61 vs. 106±62 vs. 61±44 ng/mL, p=0.001) and the AUCs differed (1503±1173 vs. 953±718 vs. 629±360, p=0.004) in the CKD, Controls and Pregnancy groups, respectively.


Despite receiving the same dose of FCM, and with comparable levels of haematinics, the rise in hepcidin was significantly greater in CKD patients compared to healthy controls and pregnant women. The reason for this novel finding is unclear, and requires further study. Finally, the ferritin response observed in this study supports a recommendation that following administration of 1g FCM, serum ferritin should not be rechecked for at least 1-month.


  • Commercial Support – Vifor